Diltiazem in the Treatment of Calcinosis in Juvenile Dermatomyositis
Overview
Physiology
Affiliations
Subcutaneous calcifications occur in a variety of diseases, including juvenile dermatomyositis. These calcifications cause disabling symptoms that do not always respond to immunosuppressant therapy. The calcium antagonist diltiazem reduces subcutaneous calcifications in CREST syndrome and in isolated cases of children with dermatomyositis. Our study was performed to determine the effects of diltiazem when used as adjunctive therapy in children with dermatomyositis.
Calcinosis in dermatomyositis: Origins and possible therapeutic avenues.
Davuluri S, Duvvuri B, Lood C, Faghihi-Kashani S, Chung L Best Pract Res Clin Rheumatol. 2022; 36(2):101768.
PMID: 35803868 PMC: 10269219. DOI: 10.1016/j.berh.2022.101768.
Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?.
Valenzuela A, Chung L J Scleroderma Relat Disord. 2022; 7(1):7-23.
PMID: 35386947 PMC: 8922676. DOI: 10.1177/23971983211053245.
Consensus-based recommendations for the management of juvenile dermatomyositis.
Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman B Ann Rheum Dis. 2016; 76(2):329-340.
PMID: 27515057 PMC: 5284351. DOI: 10.1136/annrheumdis-2016-209247.